Company news

Connect Biopharma Holdings Limited news in 2023

Connect Biopharma Holdings Limited's news releases, calls and decks from 2023, newest first.

View company

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

December 11, 2023

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

December 10, 2023

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

November 22, 2023

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

November 20, 2023

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

November 20, 2023

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

September 11, 2023

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

May 31, 2023

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

April 10, 2023

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

March 17, 2023

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

March 16, 2023

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

March 5, 2023

Decks in 2023